Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET

de Rijk, 1997, Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease, J Neurol Neurosurg Psychiatry, 62, 10, 10.1136/jnnp.62.1.10

Jenner, 2003, Oxidative stress in Parkinson's disease, Ann Neurol, 53, S26, 10.1002/ana.10483

Bandy, 1990, Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging?, Free Radic Biol Med, 8, 523, 10.1016/0891-5849(90)90152-9

Indo, 2007, Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage, Mitochondrion, 7, 106, 10.1016/j.mito.2006.11.026

Ikawa, 2009, PET imaging of redox and energy states in stroke-like episodes of MELAS, Mitochondrion, 9, 144, 10.1016/j.mito.2009.01.011

Alam, 1997, Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra, J Neurochem, 69, 1196, 10.1046/j.1471-4159.1997.69031196.x

Yoritaka, 1996, Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, Proc Natl Acad Sci U S A, 93, 2696, 10.1073/pnas.93.7.2696

Dexter, 1989, Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease, J Neurochem, 52, 381, 10.1111/j.1471-4159.1989.tb09133.x

Saggu, 1989, A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra, J Neurochem, 53, 692, 10.1111/j.1471-4159.1989.tb11759.x

Sofic, 1992, Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease, Neurosci Lett, 142, 128, 10.1016/0304-3940(92)90355-B

Schapira, 1989, Mitochondrial complex I deficiency in Parkinson's disease, Lancet, 1, 1269, 10.1016/S0140-6736(89)92366-0

Heikkila, 1984, Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice, Science, 224, 1451, 10.1126/science.6610213

Mizuno, 1987, Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion, Biochem Biophys Res Commun, 143, 294, 10.1016/0006-291X(87)90664-4

Shimura, 2000, Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, Nat Genet, 25, 302, 10.1038/77060

Valente, 2004, Hereditary early-onset Parkinson's disease caused by mutations in PINK1, Science, 304, 1158, 10.1126/science.1096284

Bonifati, 2003, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science, 299, 256, 10.1126/science.1077209

Schapira, 2008, Mitochondria in the aetiology and pathogenesis of Parkinson's disease, Lancet Neurol, 7, 97, 10.1016/S1474-4422(07)70327-7

Fukae, 2007, Mitochondrial dysfunction in Parkinson's disease, Mitochondrion, 7, 58, 10.1016/j.mito.2006.12.002

Fujibayashi, 1997, Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential, J Nucl Med, 38, 1155

Obata, 2001, Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells, Ann Nucl Med, 15, 499, 10.1007/BF02988502

Fujibayashi, 1999, Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats, Nucl Med Biol, 26, 117, 10.1016/S0969-8051(98)00049-3

Lewis, 2001, Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation, J Nucl Med, 42, 655

Lewis, 2002, Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N4- methylthiosemicarbazone), J Nucl Med, 43, 1557

Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745

Dearling, 2002, Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships, J Biol Inorg Chem, 7, 249, 10.1007/s007750100291

Snow, 1993, Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels, Ann Neurol, 34, 324, 10.1002/ana.410340304

Morrish, 1995, Clinical and [18F] dopa PET findings in early Parkinson's disease, J Neurol Neurosurg Psychiatry, 59, 597, 10.1136/jnnp.59.6.597

Morrish, 1996, An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease, Brain, 119, 585, 10.1093/brain/119.2.585

Huang, 2007, Changes in network activity with the progression of Parkinson's disease, Brain, 130, 1834, 10.1093/brain/awm086

Djaldetti, 2006, The mystery of motor asymmetry in Parkinson's disease, Lancet Neurol, 5, 796, 10.1016/S1474-4422(06)70549-X

Kempster, 1989, Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations, J Neurol Neurosurg Psychiatry, 52, 72, 10.1136/jnnp.52.1.72

Katayama, 2009, Accumulation of oxidative stress around the stroke-like lesions of MELAS patients, Mitochondrion, 9, 306, 10.1016/j.mito.2009.04.002

Abe, 2003, Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease, Neurosci Lett, 336, 105, 10.1016/S0304-3940(02)01259-4

Powers, 2008, Cerebral mitochondrial metabolism in early Parkinson's disease, J Cereb Blood Flow Metab, 28, 1754, 10.1038/jcbfm.2008.63

Hattingen, 2009, Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease, Brain, 132, 3285, 10.1093/brain/awp293